EP0000253B1 - Diagnostic kit for blood pool imaging - Google Patents
Diagnostic kit for blood pool imaging Download PDFInfo
- Publication number
- EP0000253B1 EP0000253B1 EP78300048A EP78300048A EP0000253B1 EP 0000253 B1 EP0000253 B1 EP 0000253B1 EP 78300048 A EP78300048 A EP 78300048A EP 78300048 A EP78300048 A EP 78300048A EP 0000253 B1 EP0000253 B1 EP 0000253B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- stannous
- salt
- chloride dihydrate
- glucoheptonate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- One of the methods employed in the past to image the blood pool for diagnostic purposes involves the intravenous administration of 99m Tc serum albumin which is available commercially and is a sterile pyrogen-free solution of albumin labelled with Technetium 99m having an activity of greater than 100 micro- curies/ml.
- Another method used in the past for imaging blood pools is the in vitro labelling of red blood cells (outside the host animal) followed by reinjection of the cells into the vascular system of the selected animal.
- this method it is possible to visualize both heart blood pools plus major peripheral vessels up to 3 hours after injection of the labelled cells. As can be seen, this is a complicated procedure, and therefore is a more time-consuming and expensive method.
- Still another procedure for imaging blood involves the injection of stannous pyrophosphate followed by injection of 99m Tc-pertechnetate. This technique is reported as successful in producing satisfactory imaging of blood pools.
- US Patent Specification No. 4 027 005 discloses inter alia an in vitro prepared radioactive diagnostic composition comprising a pertechnetate, stannous chloride dihydrate and a glucoheptonate salt, the preferred minimum weight of glucoheptonate being 200 times that of the stannous compound. This composition is primarily for use in examination of the kidneys.
- a diagnostic kit suitable for the radioactive labelling of red blood cells in vivo, thus making possible the imaging of blood pools within the circulatory system of the patient being examined.
- a novel chemical composition comprising a lyophilized mixture of a glucoheptonate salt and a pharmaceutically acceptable stannous salt in the ratio of 25 parts by weight of glucoheptonate salt to 3 parts by weight of stannous salt measured as calcium glucoheptonate and stannous chloride dihydrate or approximately 22.9 parts of glucoheptonate ion to 1.32 parts of tin calculated as available stannous ion.
- An important feature of the present invention is the provision of an individual diagnostic kit containing a non-toxic stannous salt capable of supplying an amount of stannous ion equivalent to at least 2.5 mg and no more than 4.0 mg of stannous chloride dihydrate. Less than 2.5 mg of the stannous chloride does not provide sufficient stannous ion to effect a satisfactory degree of labelling of red blood cells. Because of the known toxicity of stannous salts, no more than 4 mg of stannous chloride dihydrate or a stannous salt containing an equivalent amount of stannous ion should be incorporated in an individual dosage kit.
- the present invention also includes the process for the preparation of the novel chemical composition and the diagnostic method for imaging blood pools in patients suspected of having abnormalities in the circulatory system.
- a sterile solution of a non-toxic pharmaceutically acceptable salt of glucoheptonic acid e.g., calcium glucoheptonate
- a non-toxic stannous salt in a ratio of 25 parts by weight of glucoheptonate salt to 3 parts by weight of stannous salt, calculated as calcium glucoheptonate and stannous chloride dihydrate.
- the solution is adjusted to a neutral pH 6-8, subdivided, and lyophilized to produce individual vials containing a dry, sterile mixture comprising 25 mg. calcium glucoheptonate and 3 mg. stannous chloride dihydrate.
- a vial containing the dry, sterile mixture of calcium glucoheptonate and stannous chloride dihydrate is reconstituted by mixing with 2-8 ml. of a USP saline solution.
- the reconstituted solution is then used for injection of the patient to be examined. After a period of 30 minutes, a second injection of 2-8 ml. of a sterile saline solution of sodium pertechnetate is made. Following the injection of sodium pertechnetate, it is possible, after waiting from 30 seconds to 2 minutes, to image the blood pools in the patient being examined.
- a solution is prepared under sterile conditions with 25 g. of calcium glucoheptonate in sterile pyrogen-free water which has been purged with nitrogen.
- the solution of calcium glucoheptonate is stored and purged under nitrogen.
- 3 g. of stannous chloride dihydrate is dissolved in 1 ml. of hydrochloric acid, and the resulting solution diluted with nitrogen-purged, sterile water to a volume of 10 ml.
- the stannous chloride dihydrate solution is then added to the calcium glucoheptonate with stirring and flushing with nitrogen.
- the solution is mixed thoroughly, and the pH is adjusted to neutrality with a solution of sterile 1N sodium hydroxide solution.
- the volume is then adjusted to 2000 ml.
- each vial contains 25 mg. of calcium glucoheptonate and 3 mg. of stannous chloride dihydrate.
- a solution of sodium chloride for injection USP (2 ml.) is added to a vial containing a lyophilized mixture of 3 mg. of stannous chloride dihydrate and 25.0 mg. calcium glucoheptonate.
- the resulting solution is used for the intravenous injection of patients for the purpose of imaging the blood pools for diagnostic purposes.
- the amount of solution used is based on the weight of the patient and sufficient volume is used so that 30 mcg./kg. of stannous ion, measured as stannous chloride dihydrate, is injected. It is recommended that no more than the contents of one vial be administered to any patient.
- a sterile saline solution of sodium pertechnetate-Tc99m (2-20 mCi) is injected. This tags the red blood cells and permits imaging of the blood pools of the patient being examined almost immediately (from 30 seconds to 2 minutes).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
- One of the methods employed in the past to image the blood pool for diagnostic purposes involves the intravenous administration of 99m Tc serum albumin which is available commercially and is a sterile pyrogen-free solution of albumin labelled with Technetium 99m having an activity of greater than 100 micro- curies/ml.
- In utilizing this method of blood pool imaging, it is important to predose the patient immediately prior to the attempted visualization of the blood pool, since the 99m Tc serum albumin is very rapidly lost from the blood stream by exchange in the kidney.
- Another method used in the past for imaging blood pools is the in vitro labelling of red blood cells (outside the host animal) followed by reinjection of the cells into the vascular system of the selected animal. By this method, it is possible to visualize both heart blood pools plus major peripheral vessels up to 3 hours after injection of the labelled cells. As can be seen, this is a complicated procedure, and therefore is a more time-consuming and expensive method.
- Still another procedure for imaging blood involves the injection of stannous pyrophosphate followed by injection of 99m Tc-pertechnetate. This technique is reported as successful in producing satisfactory imaging of blood pools.
- US Patent Specification No. 4 027 005 discloses inter alia an in vitro prepared radioactive diagnostic composition comprising a pertechnetate, stannous chloride dihydrate and a glucoheptonate salt, the preferred minimum weight of glucoheptonate being 200 times that of the stannous compound. This composition is primarily for use in examination of the kidneys.
- In accordance with the present invention, there is provided a diagnostic kit suitable for the radioactive labelling of red blood cells in vivo, thus making possible the imaging of blood pools within the circulatory system of the patient being examined. As an integral part of the diagnostic kit of the present invention, there is also provided a novel chemical composition comprising a lyophilized mixture of a glucoheptonate salt and a pharmaceutically acceptable stannous salt in the ratio of 25 parts by weight of glucoheptonate salt to 3 parts by weight of stannous salt measured as calcium glucoheptonate and stannous chloride dihydrate or approximately 22.9 parts of glucoheptonate ion to 1.32 parts of tin calculated as available stannous ion.
- An important feature of the present invention is the provision of an individual diagnostic kit containing a non-toxic stannous salt capable of supplying an amount of stannous ion equivalent to at least 2.5 mg and no more than 4.0 mg of stannous chloride dihydrate. Less than 2.5 mg of the stannous chloride does not provide sufficient stannous ion to effect a satisfactory degree of labelling of red blood cells. Because of the known toxicity of stannous salts, no more than 4 mg of stannous chloride dihydrate or a stannous salt containing an equivalent amount of stannous ion should be incorporated in an individual dosage kit.
- The present invention also includes the process for the preparation of the novel chemical composition and the diagnostic method for imaging blood pools in patients suspected of having abnormalities in the circulatory system.
- In accordance with the process of the present invention, a sterile solution of a non-toxic pharmaceutically acceptable salt of glucoheptonic acid, e.g., calcium glucoheptonate, is mixed with a non-toxic stannous salt in a ratio of 25 parts by weight of glucoheptonate salt to 3 parts by weight of stannous salt, calculated as calcium glucoheptonate and stannous chloride dihydrate.
- The solution is adjusted to a neutral pH 6-8, subdivided, and lyophilized to produce individual vials containing a dry, sterile mixture comprising 25 mg. calcium glucoheptonate and 3 mg. stannous chloride dihydrate.
- In utilizing the kit of the present invention for imaging the blood pools of a patient to diagnose abnormalities in the cardiovascular system, a vial containing the dry, sterile mixture of calcium glucoheptonate and stannous chloride dihydrate is reconstituted by mixing with 2-8 ml. of a USP saline solution. The reconstituted solution is then used for injection of the patient to be examined. After a period of 30 minutes, a second injection of 2-8 ml. of a sterile saline solution of sodium pertechnetate is made. Following the injection of sodium pertechnetate, it is possible, after waiting from 30 seconds to 2 minutes, to image the blood pools in the patient being examined. This "in vivo" labeling of the red blood cells is exceptionally stable and approximately 95% of the radioactivity is retained by the red blood cells for at least 6 hours following injection. This simple procedure avoids the instability of the human serum albumin/99m Tc injection of the prior art as well as the expense and inconvenience of the in vitro labeling of the red blood cells noted as an alternate prior art method.
- A solution is prepared under sterile conditions with 25 g. of calcium glucoheptonate in sterile pyrogen-free water which has been purged with nitrogen. The solution of calcium glucoheptonate is stored and purged under nitrogen. In a separate container, 3 g. of stannous chloride dihydrate is dissolved in 1 ml. of hydrochloric acid, and the resulting solution diluted with nitrogen-purged, sterile water to a volume of 10 ml. The stannous chloride dihydrate solution is then added to the calcium glucoheptonate with stirring and flushing with nitrogen. The solution is mixed thoroughly, and the pH is adjusted to neutrality with a solution of sterile 1N sodium hydroxide solution. The volume is then adjusted to 2000 ml. with sterile, nitrogen-purged water and subdivided into vials, each containing 2 ml. of the solution. The vials are then lyophilized and sealed under nitrogen. Each vial contains 25 mg. of calcium glucoheptonate and 3 mg. of stannous chloride dihydrate.
- A solution of sodium chloride for injection USP (2 ml.) is added to a vial containing a lyophilized mixture of 3 mg. of stannous chloride dihydrate and 25.0 mg. calcium glucoheptonate. The resulting solution is used for the intravenous injection of patients for the purpose of imaging the blood pools for diagnostic purposes. The amount of solution used is based on the weight of the patient and sufficient volume is used so that 30 mcg./kg. of stannous ion, measured as stannous chloride dihydrate, is injected. It is recommended that no more than the contents of one vial be administered to any patient. After waiting a period of 30 minutes, a sterile saline solution of sodium pertechnetate-Tc99m (2-20 mCi) is injected. This tags the red blood cells and permits imaging of the blood pools of the patient being examined almost immediately (from 30 seconds to 2 minutes).
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA280,764A CA1105815A (en) | 1977-06-17 | 1977-06-17 | Red blood cell labelling kit |
CA280764 | 1977-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000253A1 EP0000253A1 (en) | 1979-01-10 |
EP0000253B1 true EP0000253B1 (en) | 1981-10-28 |
Family
ID=4108910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78300048A Expired EP0000253B1 (en) | 1977-06-17 | 1978-06-15 | Diagnostic kit for blood pool imaging |
Country Status (8)
Country | Link |
---|---|
US (1) | US4300569A (en) |
EP (1) | EP0000253B1 (en) |
JP (1) | JPS5417129A (en) |
CA (1) | CA1105815A (en) |
DE (1) | DE2861257D1 (en) |
DK (1) | DK269578A (en) |
IE (1) | IE47091B1 (en) |
IT (1) | IT1105145B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4372294A (en) * | 1980-09-25 | 1983-02-08 | The Massachusetts General Hospital | Method and apparatus for radiolabeling red blood cells |
US4443426A (en) * | 1982-06-14 | 1984-04-17 | Yale University | Blood agent |
US4581221A (en) * | 1983-08-29 | 1986-04-08 | Medi Nuclear Corporation, Inc. | Ulcer detection |
US4755375A (en) * | 1984-01-27 | 1988-07-05 | Associated Universities, Inc. | Method and kit for the selective labeling of red blood cells in whole blood with TC-99M |
JPS61103841A (en) * | 1984-10-26 | 1986-05-22 | Nippon Mejifuijitsukusu Kk | Stable stannous chloride composition to be fed radioactivity technetium mark |
US4789541A (en) * | 1985-10-04 | 1988-12-06 | Davis Michael H | Method and composition for in vivo radiolabeling of red blood cells with 99m Tc |
US4692324A (en) * | 1985-10-04 | 1987-09-08 | Davis Michael H | Method and composition for in vivo radiolabeling of red blood cells with 99m Tc |
EP0754046A1 (en) * | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5529189A (en) * | 1995-08-02 | 1996-06-25 | Daxor Corporation | Syringe assembly for quantitative measurement of radioactive injectate and kit having same |
US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
DE102007053722B4 (en) | 2007-11-10 | 2011-08-25 | Amphenol-Tuchel Electronics GmbH, 74080 | Hermaphroditic connector |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743714A (en) * | 1970-12-04 | 1973-07-03 | Cis Radiopharmaceuticals Inc | Novel carrier preparations for injectable radioactive compositions |
CA1027135A (en) * | 1973-06-11 | 1978-02-28 | Research Corporation | Bone-seeking technetium-99m complex |
US4027005A (en) * | 1974-06-07 | 1977-05-31 | New England Nuclear Corporation | Diagnostic agents |
US4042677A (en) * | 1974-08-29 | 1977-08-16 | Union Carbide Corporation | Technetium-99m labeled radiodiagnostic agents and method of preparation |
GB1535847A (en) * | 1976-03-19 | 1978-12-13 | Radiochemical Centre Ltd | Technetium-99m labelled tin colloid for body scanning |
US4054645A (en) * | 1976-08-24 | 1977-10-18 | Minnesota Mining And Manufacturing Company | Radiodiagnostic complexes employing fluorine-containing tin reducing agents |
US4070493A (en) * | 1977-03-16 | 1978-01-24 | Merck & Co., Inc. | Diagnostic kit |
-
1977
- 1977-06-17 CA CA280,764A patent/CA1105815A/en not_active Expired
-
1978
- 1978-06-12 IT IT49830/78A patent/IT1105145B/en active
- 1978-06-14 IE IE1195/78A patent/IE47091B1/en not_active IP Right Cessation
- 1978-06-15 DE DE7878300048T patent/DE2861257D1/en not_active Expired
- 1978-06-15 EP EP78300048A patent/EP0000253B1/en not_active Expired
- 1978-06-15 DK DK269578A patent/DK269578A/en not_active Application Discontinuation
- 1978-06-17 JP JP7274778A patent/JPS5417129A/en active Granted
-
1980
- 1980-02-25 US US06/124,166 patent/US4300569A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0000253A1 (en) | 1979-01-10 |
IE781195L (en) | 1978-12-17 |
IT7849830A0 (en) | 1978-06-12 |
US4300569A (en) | 1981-11-17 |
IT1105145B (en) | 1985-10-28 |
JPS5417129A (en) | 1979-02-08 |
JPS6315248B2 (en) | 1988-04-04 |
CA1105815A (en) | 1981-07-28 |
DK269578A (en) | 1978-12-18 |
IE47091B1 (en) | 1983-12-14 |
DE2861257D1 (en) | 1982-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4500507A (en) | Diagnostic composition for radiologic imaging of neoplasms in the body and method of preparation | |
EP0000253B1 (en) | Diagnostic kit for blood pool imaging | |
JPS5896031A (en) | Stable radioactive diagnosticum | |
AU638363B2 (en) | Process for preparing a radiopharmaceutical composition | |
US4027005A (en) | Diagnostic agents | |
PL165699B1 (en) | Method of producing a radiopharmaceutical agent | |
KR860001565B1 (en) | Method for preparing radioactive diagnostic agent | |
US4113850A (en) | Composition for the diagnostic visualization of neoplastic tissues | |
JPS6126887B2 (en) | ||
KR850001870B1 (en) | A process for preparing non-radioactive carrier composition and radioactive diagnostic agent for bon-scanning | |
EP0438502B1 (en) | Technetium imaging agents | |
KR100430061B1 (en) | Radioisotope labeled complex of glucose derivatives and kit for preparation thereof | |
JP3051591B2 (en) | Anti-adhesion agent for thallium-201 container | |
US4118468A (en) | Technetium-99m-labelled diagnostic agent for kidney scanning and process for its manufacture | |
US4946668A (en) | Tumor imaging with technetium labelled glucarate | |
RU2824276C2 (en) | Method of combined radionuclide therapy of differentiated thyroid cancer with metastatic involvement of lungs and skeleton | |
AU609569B2 (en) | Tc-99m mononuclide complex compound | |
EP0960623A2 (en) | Kit for the single step preparation of pentavalent technetium 99mTc(V)-DMSA | |
Ponto | Choosing a radiopharmaceutical for cardiac blood pool imaging | |
Van Der Schoot et al. | Tc99m Labelling of Red Blood-Cells and their Clinical Application | |
Shaeffer | Lack of enhanced lysis of fibrinogen-I131 by anticoagulants in tumor-bearing rats | |
Weininger et al. | Technetium-99m-BIDA. A potential cholescintigraphic agent for icteric patients | |
Seifert et al. | ROTOP-MYOSPECT–A 99mTc-Radiopharmaceutical for Myocardial Perfusion Diagnostics | |
JPH09143200A (en) | Macroagglutinative human serum albumin labeled with 111-in, its preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2861257 Country of ref document: DE Date of ref document: 19820107 |
|
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 78300048.2 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19970319 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19970326 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19970404 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19970410 Year of fee payment: 20 Ref country code: BE Payment date: 19970410 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19970421 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19970523 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19970630 Year of fee payment: 20 |
|
BE20 | Be: patent expired |
Free format text: 980615 *MERCK SHARP & DOHME (I.A.) CORP. |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980614 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980615 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980615 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Effective date: 19980614 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 19980615 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78300048.2 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |